Justin Sullivan/Getty Images News
Gilead Sciences (NASDAQ:GILD) has reached a $202M deal with a group of attorneys general in the U.S. to settle allegations that its promotional speaker programs for its HIV drugs violated federal anti-kickback laws.
New York Attorney General Letitia James announced